Introduction
We have previously reported a genetically modified bacteria strain, Salmonella typhimurium A1, selected for anticancer activity in vivo. S. typhimurium A1 is auxotrophic (leu/arg-dependent). 1 The strain grows in tumor xenografts. In sharp contrast, normal tissue is cleared of these bacteria even in immunodeficient athymic mice. In vitro, the GFP-expressing bacteria grew in the cytoplasm of PC-3 human prostate cancer cells and caused nuclear destruction. These effects were visualized in cells labeled with GFP in the nucleus and red fluorescent protein in the cytoplasm. In vivo, the bacteria caused tumor inhibition and regression of tumors visualized by whole-body imaging. The bacteria, introduced i.v. or intratumorally, invaded and replicated intracellularly in PC-3 prostate cancer cells labeled with red fluorescent protein grafted into nude mice. When the bacteria were injected intratumorally, the tumor completely regressed by day 20. There were no obvious adverse effects on the host when the bacteria were injected by either route. The S. typhimurium A1 strain grew throughout the tumor, including viable malignant tissue. This result is in marked contrast to bacteria previously tried for cancer Salmonella typhimurium double leu-arg auxotrophs have been shown to be highly effective as antitumor agents in nude mouse models of human metastatic cancer. In order to proceed to clinical development of the S. typhimurium double auxotroph, termed a1-R, it is necessary to evaluate antitumor efficacy in immunocompetent mice. In the present study, we have observed the efficacy of a1-R on the Lewis lung (LLC) carcinoma in vitro as well as in C57BL/6 (C57) immunocompetent mice. In vitro, a1-R treatment of LLC began to induce cell death within one hour. Various doses and schedules of a1-R were administered to C57 mice implanted with LLC, including bolus single intravenous injection; medium dose with weekly intravenous administration; and metronomic treatment with small intravenous doses twice a week. Bolus treatment was toxic to the immunocompetent host, in contrast to nude mice. Lower-dose weekly doses and metronomic doses were well tolerated by the immunocompetent host. Weekly intravenous injection with 2 x 10 7 bacteria and twice a week intravenous injection with 10 7 bacteria significantly inhibited metastasis formation, while bolus injection was toxic. Intrathoracic administration was performed with 10 8 a1-R bacteria injected into Lewis lung-bearing C57 mice weekly for three weeks. Lung metastasis was significantly inhibited by intrathoracic bacterial administration, without toxicity. the results in this report, demonstrating the anti-metastatic efficacy of S. typhimurium a1-R in immunocompetent mice, indicate the clinical potential of bacterial therapy of cancer. therapy that were confined to necrotic areas of the tumor, which may account, in part, for the strain's unique antitumor efficacy. [2] [3] [4] [5] [6] [7] [8] [9] In order to increase tumor-targeting capability of A1, the strain was re-isolated after infection of a human colon tumor growing in nude mice. The tumor-isolated strain, termed A1-R, had increased targeting for tumor cells in vivo as well as in vitro compared with A1. Treatment with A1-R resulted in highly effective tumor targeting, including viable tumor tissue and significant tumor shrinkage in mice with s.c. or orthotopic human breast cancer xerographs. Survival of the treated animals was significantly prolonged. Forty percent of treated mice were cured completely and survived as long as non-tumor-bearing mice.
Efficacy against lung metastasis with a tumor-targeting mutant of Salmonella typhimurium in immunocompetent mice
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A1-R was used to treat metastatic PC-3 human prostate tumors that had been orthotopically implanted in nude mice. GFP was used to image tumor and metastatic growth. Of the 10 mice with the PC-3 tumors that were injected weekly with S. typhimurium A1-R, 7 were alive and well at the time the last untreated mouse died. Four A1-R-treated mice remain alive and well 6 mo after implantation. Ten additional non-tumor-bearing mice were injected weekly to determine the toxicity of S. typhimurium A1-R. No toxic effects were observed. animals had a significantly better survival than the i.v.-treated group as well as over the control group. 16 Leschner et al. observed a rapid increase of TNFα in blood, in addition to other pro-inflammatory cytokines, after S. typhimurium treatment of tumors. This induced a great influx of blood into the tumors by vascular disruption and bacteria were flushed into the tumor along with the blood. 17 In order to further study tumor-vascular disruption by bacteria, red fluorescent protein (RFP)-expressing Lewis lung cancer cells (LLC-RFP) were transplanted subcutaneously in the ear, back skin and footpad of nestin-driven green fluorescent protein (GFP) (ND-GFP) transgenic nude mice, which selectively express GFP in nascent blood vessels. The ear tumor had more abundant blood vessels than that on the back or footpad. Tumor vascularity correlated positively with vascular disruption and tumor efficacy of A1-R suggesting that bacteria efficacy on tumors involves vessel destruction which depends on the extent of vascularity of the tumor. 18 The studies described above used nude-mouse models which are T-cell deficient. It is very important to determine the anticancer efficacy of S. typhimurium in an immunocompetent host as a bridge to the clinic. The present report demonstrates the efficacy of S. typhimurium A1-R in the Lewis lung carcinoma model in immunocompetent C57B16 mice.
Results and Discussion
Confocal imaging of lung cancer cell death induced by S. typhimurium A1-R targeting in vitro. The interaction between
A new targeting strategy for primary bone tumor and lung metastasis with the modified auxotrophic strain of S. typhimurium A1-R was developed. A1-R was injected in the tail vein three times on a weekly basis. Primary bone tumor size was significantly inhibited in the treated group and lung metastasis was almost eradicated. Therefore, A1-R treatment was effective for both primary bone tumor and lung metastasis. 12 A1-R was administered to an orthotopic human pancreatic tumor in nude mice. After 7 d of treatment, the pancreatic cancer had regressed without the need for chemotherapy. 13 A1-R was administered to both axillary lymph and popliteal lymph node metastasis of human pancreatic cancer and fibrosarcoma, respectively, as well as lung metastasis of the fibrosarcoma in nude mice. The bacteria were delivered via a lymphatic channel to target the lymph node metastases and systemically via the tail vein to target the lung metastasis. The metastases were eradicated without the need of chemotherapy or any other treatment. No adverse effects were observed. 14 A1-R was shown to target and inhibit the growth of liver metastasis in a mouse model of pancreatic glioma. Locally as well as systemically administered A1-R inhibited liver metastasis of pancreatic cancer. Mice treated with A1-R given locally via intrasplenic injection or systemically via tail vein injection had a much lower hepatic and splenic tumor burden compared with control mice. Systemic treatment with intravenous A1-R also increased survival time. 15 A1-R was administered systemically or intrathecally, to spinal cord cancer in orthotopic mouse models. Untreated mice became paralyzed due to the spinal glioma growth, and treatment with A1-R either delayed or prevented paralysis. Intrathecally treated /ml) and incubated at 37°C. after 40 min, the cells were rinsed and cultured in medium containing gentamycin sulfate (20 μg/ml) to kill external, but not internal bacteria. the interaction of a1-R with tumor cells in vitro was observed with the Fluoview FV1000 confocal imaging system (olympus).
RFP-labeled Lewis lung carcinoma cells (1 x 10
6 ) were injected into the tail vein of C57 mice. On day 5, there were tumor metastases in the lung. At this time, A1-R (10 7 CFU) was injected into the tail vein of the mice every three days. On day 15, all animals were sacrificed. The excised lungs were weighed and imaged using the OV100. Fewer RFP Lewis lung carcinoma metastases were found in the A1-R treated lungs than in the lungs of the untreated mice. The weight of the lungs in the treated mice was significantly less than the weight of the lungs in the untreated control mice (p < 0.05). These results indicated that lung metastasis was strongly inhibited by systemic treatment with A1-R (Fig. 3) .
Survival of C57 mice with Lewis lung carcinoma experimental metastasis is prolonged by S. typhimurium A1-R systemic administration. RFP-labeled Lewis lung carcinoma cells (1 x 10 6 ) were injected into the tail vein of the mice. On day 5, A1-R (10 7 CFU) were injected into the tail vein of the mice every three days, six times. This treatment resulted in prolonged survival of the treated mice (Fig. 4) . The average survival time of the treated mice was 36 d compared with 23 d for the untreated mice (p = 0.001).
However, the tail vein of the mice became strongly inflamed after repeated tail-vein injection of bacteria, which had to be discontinued. As a consequence, the mice in the treated group eventually died. Tail vein injection became a dose-limiting toxicity.
S. typhimurium A1-R expressing GFP and Lewis lung carcinoma cells, labeled with RFP in the cytoplasm and GFP in the nucleus, was observed with the Fluoview FV1000 confocal microscope (Olympus). GFP-expressing A1-R invaded the dual-color Lewis lung carcinoma cells and rapidly began to induce cell death as early as 60 min after infection (Fig. 1) . The cells appeared to die by bursting 90 min after bacteria targeting. This result showed virulence of A1-R for Lewis lung carcinoma cells (Fig. 1) .
Lewis lung carcinoma metastasis in the lung of immunocompetent mice was targeted by S. typhimurium A1-R after systemic administration. RFP-labeled Lewis lung carcinoma cells (1 x 10 6 ) were injected into the tail vein to obtain experimental lung metastasis in C57 mice. By day 5, there were tumor colonies in the lung (Fig. 2) . At that time, A1-R bacteria (10 7 CFU) were injected into the tail vein of the C57 mice. The lungs were excised on day 2 and day 4 after A1-R administration from sacrificed mice. Tumor targeting by S. typhimurium A1-R was observed with the OV100 Small Animal Imaging System. The RFP-Lewis lung carcinoma experimental metastasis and GFPlabeled A1-R were observed in the lungs of C57 mouse on day 2 (Fig. 2B) . By day 4, A1-R grew inside the targeted RFP metastases and caused the metastases to lose their red fluorescence due to the cytotoxicity of A1-R (Fig. 2) .
Inhibition of experimental Lewis lung carcinoma metastasis by S. typhimurium A1-R administered systemically. ) were injected into the tail vein to obtain experimental lung metastasis in C57 mice. on day 5, S. typhimurium a1-R bacteria (10 7 CFU) were injected into the tail vein of C57 mice. animals were sacrificed and the lungs were excised on day 2 and dayInhibition of Lewis lung carcinoma experimental metastasis by regional administration of S. typhimurium A1-R. Lewis lung carcinoma cells expressing RFP (1 x 10 6 ) were injected in the tail vein of C57 mice. A1-R (10 8 CFU) was injected into the thoracic cavity of Lewis lung carcinoma-bearing C57 mice weekly for three weeks beginning on day 5 after cancer cell implantation. All animals were then sacrificed. The excised lungs were weighed and imaged using the OV100. RFP-labeled Lewis lung carcinoma experimental metastasis was inhibited in the A1-R-treated mice compared with the lungs of the untreated mice. The weight of lungs of the treated mice was significantly less than the weight of the lungs of the untreated mice (p < 0.05). These results indicated that lung metastasis was inhibited by regional bacteria therapy, in this case by intrathoracic administration (Fig.  5) . No toxicity was observed.
Safety of S. typhimurium A1-R administration in C57 immunocompetent mice. C57 mice were given a bolus treatment of 5 x 10 7 CFU A1-R in 100 μl PBS with a single intravenous Figure 3 . efficacy of S. typhimurium a1-R treatment on RFp-labeled Lewis lung experimental lung metastasis in C57 immunocompetent mice. Female C57 immunocompetent mice, age 6 weeks, were injected with RFp-expressing Lewis lung carcinoma cells (1 x 10 6 in 100 μl pBs) into the tail vein. on day 5, S. typhimurium a1-R (10 7 CFU) were injected into the tail vein of the mice every three days. on day 15, all animals were sacrificed. the excised lungs were weighed and imaged using the olympus oV100. (a) Fewer RFp-labeled lung metastasis were found in the lungs of mice treated with S. typhimurium a1-R-GFp than in the lungs of the untreated mice. (B) RFp-labeled lung metastasis in the lungs of the untreated C57 control mice. (C) the weight of the lungs from mice treated with S. typhimurium a1-R-GFp was significantly less than the weight of the lungs of the untreated control mouse. 6 in 100 μl pBs) into the tail vein. Beginning at day 5, S. typhimurium a1-R bacteria (10 7 CFU) were injected into the tail vein of the mice twice a week for three weeks. the survival of mice was determined for both treated and untreated groups.
injection; or a medium intravenous injection dose of 2 x 10 7 CFU for 3 weeks; or a metronomic dose of 10 7 CFU, twice a week by intravenous administration for 3 weeks. Bolus treatment was toxic to the host. The animals showed inactivity, loss of body weight, inability to groom and ruffling of fur. Fifty percent of the mice died by day 3. The metronomic treatment was best tolerated by the mice. Animals had only slight body weight loss and had normal fur and activity.
Intrathoracic administration allowed 10 8 CFU A1-R to be administered to the host with no obvious toxicity with a weekly infection schedule for 3 weeks. The animals could tolerate higher doses of A1-R bacteria and more frequent administration with this route.
S. typhimurium also targets tumor vasculature. 17, 18 Suitably modified liposomes 19 or nano-particles 20 can also target tumor vasculature which suggests combining them with S. typhimurium A1-R for even greater efficacy. Such therapies can be better followed with state-of-the-art optimal tomography 21 or magnetic resonance spectroscopy based on tumor metabolism. 22 Lung cancer targeting by S. typhimurium A1-R may also be enhanced by other agents which target lung cancer such as an epidermal growth factor receptor (EGFP) tyronsine kinase inhibitor. 23 The goal is to develop a tumor-seeking S. typhimurium strain that can kill primary and metastatic cancer without toxic effects to an immunocompetent host and without the need for combination with toxic chemotherapy. Toward this goal, S. typhimurium, A1-R was developed, that has greatly increased anti-tumor efficacy but maintains its original auxotrophy for leu-arg that prevents it from mounting a continuous infection in normal tissues. In the present report, A1-R was effective in monotherapy on mouse models of experimental lung metastatic cancer in an immunocompetent C57 mouse. Future studies will be aimed to bring S. typhimurium A1-R treatment of cancer to the clinic. 24 
Materials and Methods
Preparation of bacteria. The S. typhimurium A1-R bacteria were grown overnight on LB medium and then diluted 1:10 in LB medium. Bacteria were harvested at late-log phase, washed with PBS, and then diluted in PBS. Bacteria were then injected into the tail vein of nude mice.
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Cancer cell culture. Lewis lung carcinoma cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM glutamine (Gibco-BRL, Life Technologies, Inc.). The cell line was cultured at 37°C in a 5% incubator.
RFP vector production and transduction of the Lewis lung cancer cell line were performed as follows. [25] [26] [27] The RFP (DsRed-2) gene (Clontech Laboratories) was inserted in the retroviral-based mammalian expression vector pLNCX (Clontech) to form the pLNCX DsRed-2 vector as previously described in references 25-27. For RFP gene transduction, 70% confluent Lewis lung carcinoma cells were incubated with a 1:1 precipitated Figure 5 . S. typhimurium a1-R inhibition of Lewis lung carcinoma experimental metastasis with intrathoracic bacteria administration. Female C57 immunocompetent mice, aged 6 weeks, were injected with RFp-expressing Lewis lung carcinoma cells (1 x 10 6 in 100 μl pBs) into the tail vein. Beginning at day 5, 1 x 10 8 CFU S. typhimurium were injected into thoracic cavity weekly for three weeks. all animals were sacrificed at week 4. the excised lungs were weighed and imaged using the olympus oV100. (a) RFp-labeled metastasis in the lungs of untreated C57 control mice. (B) RFp-labeled metastasis in the lungs of mice treated by intrathoracic S. typhimurium a1-R-GFp. (C) the weight of the lungs from mice treated with intrathoracic S. typhimurium a1-R compared with the weight of the lungs from untreated mice.
